Squamous cell carcinoma of gingivobuccal complex: Literature, evidences and practice

• Published in: Journal of head & neck physicians and surgeons 2018-01, Vol.6 (1), p.18-28
• Main Authors: Mandlik, Dushyant, Nair, Suraj, Patel, Kaustubh, Gupta, Karan, Patel, Purvi, Patel, Parin, Sharma, Nitin, Joshipura, Aditya, Patel, Mitesh
• Format: Article
• Language: English
• Subjects: Gingivobuccal cancer; marginal mandibulectomy; neck dissection; oral cancer
• ISSN: 2347-8128; 2347-8128
• DOI: 10.4103/jhnps.jhnps_19_18

Gingivobuccal cancer (GBC) is the most common oral cavity cancer (OCC). Its incidence is increasing with increased use of tobacco and areca nut chewing in third world countries especially the Indian subcontinent. It comprises buccal mucosa, gingivobuccal sulcus, alveolus and retromolar area cancers. OCCs comprise 12% of all male cancers in India, 40% of these are GBCs. Certain precancerous conditions and lesions such as submucous fibrosis, leukoplakia and erythroplakia are known. In special situations such as trismus, examination and early detection becomes difficult. Computed tomography scan is an investigation of choice. Tumor node metastasis staging gives adequate information for treatment selection and prognosis. Surgery remains the mainstay of curative treatment. Due to its unique proximity to mandible and posteriorly infratemporal fossa, extent of surgery remains critical to provide cure with satisfactory functional and esthetic outcomes. Marginal mandibulectomy has consistently provided these results in carefully selected patients. More advanced cancers need segmental or hemimandibulectomy and appropriate reconstruction-preferably free microvascular bone and soft-tissue transfer. Radiotherapy is used in adjuvant setting to reduce locoregional recurrences. It can also be used as palliative modality in advance cases. The role of chemotherapy is investigational; however, criteria have been defined for its use concurrent with radiation in adjuvant postoperative settings in high-risk patients. Cure rates are as high as 85% in early stages and as low as 0%-20% in advance stages. Follow-up strategy is aimed at detection of locoregional failure initially and prevention and management of second cancers.